VALFIX Medical Announces Issuance of U.S. Patent for Its Heart Valve Repair and Replace Technology

Tel-Aviv, Israel (May 13th, 2019) – VALFIX Medical Ltd. announces the issuance of US Patent No. 10,278,820 titled "Percutaneous valve repair and replacement" issued May 7, 2017. VALFIX Medical is developing trans-catheter solutions for patients suffering from valvular heart disease and heart failure.

"It is exciting to receive this patent as it confirms our technology patentability; our technology is unique and distinct in the market," stated Eli Bar, CEO and Founder of VALFIX Medical. " This patent granted confirms and protects our core technology and adds significant value to our stakeholders"

VALFIX Medical technology is distinguished in its approach to offer both repair and replacement treatment in one procedure. This unique toolbox approach gives more options for interventional cardiologists to deliver the most effective therapy to this complex condition.

Concurrently with the issuance of this patent, VALFIX Medical continues to develop its patent portfolio with other patents in preparation and pending.


About VALFIX Medical:


VALFIX Medical is developing the first complete trans-catheter solution which, based on its multi-wire technology, combines repair and replacement treatments for the Mitral and the Tricuspid valves; offering a viable alternative to open heart surgery.


To learn more about VALFIX Medical visit our website at www.valfixmed.com or contact us directly at info@valfixmed.com


Media Contact:


Devra Igra +972 73 374 4805 devra.igra@valfixmed.com

© 2020 by VALFIX Medical Ltd.

VALFIX products are not available for sale or commercial distribution.